AtriCure, Inc. has received a CE Mark for the AtriClip PRO2 left atrial appendage exclusion system, which offers increased functionality to occlude the appendage during minimally invasive surgical procedures.
The device was previously launched in April 2016 with FDA 510(k) clearance in the United States.
Example of AtriClip system. (Credit: Hellerhoff /Wikimedia Commons)
The addition of the AtriClip PRO2 device expands the company’s left atrial appendage product offerings and now provides an ambidextrous locking and trigger-style clip closing mechanism, handle-based active articulation levers, and a hoopless end effector.
The features have improved the ease of use and time it takes to manage the left atrial appendage, according to the company.
AtriCure, Inc., based in Mason, OH, is a medical device company providing treatments for atrial fibrillation and left atrial appendage management.
![An illustration showing the Edwards Lifesciences Sapien M3 transcatheter mitral valve replacement (TMVR) system's valve being placed in the heart. [Image courtesy of Edwards Lifesciences]](https://www.medicaldesignandoutsourcing.com/wp-content/uploads/2025/04/Edwards-Lifesciences-Sapien-M3-TMVR-valve-delivery-268x170.jpg)
